Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
24 03 2020
24 03 2020
Historique:
received:
20
12
2019
accepted:
11
02
2020
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Plasma ADAMTS13 circulates in a folded conformation that is stabilized by an interaction between the central Spacer domain and the C-terminal CUB (complement components C1r and C1s, sea urchin protein Uegf, and bone morphogenetic protein-1) domains. Binding of ADAMTS13 to the VWF D4(-CK) domains or to certain activating murine monoclonal antibodies (mAbs) induces a structural change that extends ADAMTS13 into an open conformation that enhances its function. The objective was to characterize the mechanism by which conformational activation enhances ADAMTS13-mediated proteolysis of VWF. The activating effects of a novel anti-Spacer (3E4) and the anti-CUB1 (17G2) mAbs on the kinetics of proteolysis of VWF A2 domain fragments by ADAMTS13 were analyzed. mAb-induced conformational changes in ADAMTS13 were investigated by enzyme-linked immunosorbent assay. Both mAbs enhanced ADAMTS13 catalytic efficiency (kcat/Km) by ∼twofold (3E4: 2.0-fold; 17G2: 1.8-fold). Contrary to previous hypotheses, ADAMTS13 activation was not mediated through exposure of the Spacer or cysteine-rich domain exosites. Kinetic analyses revealed that mAb-induced conformational extension of ADAMTS13 enhances the proteolytic function of the metalloprotease domain (kcat), rather than augmenting substrate binding (Km). A conformational effect on the metalloprotease domain was further corroborated by the finding that incubation of ADAMTS13 with either mAb exposed a cryptic epitope in the metalloprotease domain that is normally concealed when ADAMTS13 is in a closed conformation. We show for the first time that the primary mechanism of mAb-induced conformational activation of ADAMTS13 is not a consequence of functional exosite exposure. Rather, our data are consistent with an allosteric activation mechanism on the metalloprotease domain that augments active site function.
Identifiants
pubmed: 32196558
pii: S2473-9529(20)31429-4
doi: 10.1182/bloodadvances.2019001375
pmc: PMC7094026
doi:
Substances chimiques
von Willebrand Factor
0
Metalloproteases
EC 3.4.-
ADAMTS13 protein, mouse
EC 3.4.24.-
ADAMTS13 Protein
EC 3.4.24.87
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1072-1080Subventions
Organisme : Medical Research Council
ID : MR/M010260/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/44/30962
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/17/33572
Pays : United Kingdom
Informations de copyright
© 2020 by The American Society of Hematology.
Références
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18578-83
pubmed: 25512499
Science. 2009 Jun 5;324(5932):1330-4
pubmed: 19498171
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18584-9
pubmed: 25512528
J Biol Chem. 2017 Apr 7;292(14):5760-5769
pubmed: 28209710
Br J Haematol. 2005 Apr;129(1):93-100
pubmed: 15801961
Blood. 2012 Apr 19;119(16):3836-43
pubmed: 22289888
Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19274-9
pubmed: 19880749
J Thromb Haemost. 2018 Feb;16(2):378-388
pubmed: 29222940
Blood. 2011 Sep 22;118(12):3212-21
pubmed: 21715306
J Thromb Haemost. 2015 Nov;13(11):2063-75
pubmed: 26391536
J Biol Chem. 2001 Nov 2;276(44):41059-63
pubmed: 11557746
Blood. 2019 Apr 25;133(17):1899-1908
pubmed: 30700419
Blood. 2015 Mar 19;125(12):1968-75
pubmed: 25564400
Blood. 2009 Sep 24;114(13):2819-28
pubmed: 19587373
Blood. 2010 Sep 23;116(12):2005-10
pubmed: 20551375
Nat Commun. 2019 Aug 22;10(1):3781
pubmed: 31439947